文献速递妇产影像

纵向评估血管生成标志物预测确诊子痫前期孕妇不良结局

Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

基于维也纳医科大学2013年1月至2020年12月前瞻性收集数据的回顾性分析,纳入323例确诊子痫前期单胎孕妇的885次产后sFlt-1/PlGF比值测量,纵向评估血管生成标志物对孕产妇及围产儿不良结局的预测效能,并与常规实验室指标比较。

要点

  • sFlt-1/PlGF比值预测围产儿不良结局的AUC为0.82,优于肌酐(AUC 0.74)。
  • sFlt-1/PlGF比值预测孕产妇不良结局的AUC为0.72,与肌酐、LDH相当。
  • LDH、肌酐与sFlt-1/PlGF比值联合预测孕产妇不良结局AUC为0.77,显著高于单用比值。

核心结论

  • 确诊子痫前期孕妇纵向 maternal serum 血管生成标志物评估是孕产妇及围产儿不良结局的良好预测指标,优于部分常规实验室参数。
  • 作者认为后续研究应聚焦子痫前期诊断后的最佳监测方案。

研究设计与样本

  • 回顾性分析2013年1月至2020年12月维也纳医科大学前瞻性收集的数据。
  • 纳入标准为确诊子痫前期的单胎妊娠,且诊断后至少两个时间点进行母体血清血管生成标志物评估。
  • 共纳入323例确诊子痫前期孕妇,获得885次诊断后sFlt-1/PlGF比值测量。

诊断标准与关键数值

  • 孕产妇复合不良结局(含ICU入住、肺水肿、子痫和/或死亡)预测:sFlt-1/PlGF比值AUC 0.72(95%CI 0.62-0.81),肌酐AUC 0.71(95%CI 0.62-0.81),LDH AUC 0.73(95%CI 0.65-0.81)。
  • 孕产妇复合不良结局预测:血小板AUC 0.65(95%CI 0.55-0.74),ALT AUC 0.59(95%CI 0.49-0.69),AST AUC 0.61(95%CI 0.51-0.71)。
  • 孕产妇复合不良结局最佳预测模型为LDH、肌酐与sFlt-1/PlGF比值联合,AUC 0.77(95%CI 0.68-0.85),显著高于单用sFlt-1/PlGF比值(P=0.037)。
  • 围产儿复合不良结局(含死产、新生儿死亡、胎盘早剥、NICU入住、脑室内出血、坏死性小肠结肠炎、呼吸窘迫综合征和/或机械通气支持)预测:sFlt-1/PlGF比值AUC 0.82(95%CI 0.75-0.89),肌酐AUC 0.74(95%CI 0.67-0.80),比值优于单用肌酐(P<0.001)。
  • 围产儿复合不良结局预测:LDH AUC 0.65(95%CI 0.53-0.74),血小板AUC 0.57(95%CI 0.44-0.67),ALT AUC 0.58(95%CI 0.48-0.67),AST AUC 0.58(95%CI 0.48-0.67);无任何标志物组合优于单用sFlt-1/PlGF比值(所有P>0.05)。

临床应用与阅片要点

  • 作者认为在确诊子痫前期孕妇中,纵向母体血清血管生成标志物评估是孕产妇及围产儿不良结局的良好预测指标,优于部分常规实验室参数。
  • 作者认为后续研究应聚焦子痫前期诊断后的最佳监测方案。

局限性

  • 作者在结论中指出需进一步研究以确定子痫前期诊断后的最佳监测方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Angiogenic marker assessment, such as the ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF), is known to be a useful tool in the prediction of pre-eclampsia (PE). However, evidence from surveillance strategies in pregnancies with a PE diagnosis is lacking. Therefore, we aimed to assess the predictive performance of longitudinal maternal serum angiogenic marker assessment for both maternal and perinatal adverse outcomes when compared to standard laboratory parameters in pregnancies with confirmed PE.

METHODS: This was a retrospective analysis of prospectively collected data from January 2013 to December 2020 at the Medical University of Vienna. The inclusion criteria were singleton pregnancy with confirmed PE and post-diagnosis maternal serum angiogenic marker assessment at a minimum of two timepoints. The primary outcome was the predictive performance of longitudinal sFlt-1 and PlGF assessment for adverse maternal and perinatal outcomes compared to conventional laboratory monitoring at the same time in pregnancies with confirmed PE. Composite adverse maternal outcome included intensive care unit admission, pulmonary edema, eclampsia and/or death. Composite adverse perinatal outcome included stillbirth, neonatal death, placental abruption, neonatal intensive care unit admission, intraventricular hemorrhage, necrotizing enterocolitis, respiratory distress syndrome and/or mechanical ventilator support.

RESULTS: In total, 885 post-diagnosis sFlt-1/PlGF ratio measurements were obtained from 323 pregnant women with confirmed PE. For composite adverse maternal outcome, the highest standalone predictive accuracy was obtained using maternal serum sFlt-1/PlGF ratio (area under the receiver-operating-characteristics curve (AUC), 0.72 (95% CI, 0.62-0.81)), creatinine (AUC, 0.71 (95% CI, 0.62-0.81)) and lactate dehydrogenase (LDH) levels (AUC, 0.73 (95% CI, 0.65-0.81)). Maternal platelet levels (AUC, 0.65 (95% CI, 0.55-0.74)), serum alanine aminotransferase (ALT) (AUC, 0.59 (95% CI, 0.49-0.69)) and aspartate aminotransferase (AST) (AUC, 0.61 (95% CI, 0.51-0.71) levels had poor standalone predictive accuracy. The best prediction model consisted of a combination of maternal serum LDH, creatinine levels and sFlt-1/PlGF ratio, which had an AUC of 0.77 (95% CI, 0.68-0.85), significantly higher than sFlt-1/PlGF ratio alone (P = 0.037). For composite adverse perinatal outcome, the highest standalone predictive accuracy was obtained using maternal serum sFlt-1/PlGF ratio (AUC, 0.82 (95% CI, 0.75-0.89)) and creatinine (AUC, 0.74 (95% CI, 0.67-0.80)) levels, sFlt-1/PlGF ratio being superior to creatinine alone (P < 0.001). Maternal serum LDH levels (AUC, 0.65 (95% CI, 0.53-0.74)), platelet count (AUC, 0.57 (95% CI, 0.44-0.67)), ALT (AUC, 0.58 (95% CI, 0.48-0.67)) and AST (AUC, 0.58 (95% CI, 0.48-0.67)) levels had poor standalone predictive accuracy. No combination of biomarkers was superior to maternal serum sFlt-1/PlGF ratio alone for prediction of composite adverse perinatal outcome (P > 0.05 for all).

CONCLUSIONS: In pregnancies with confirmed PE, longitudinal maternal serum angiogenic marker assessment is a good predictor of adverse maternal and perinatal outcomes and superior to some conventional laboratory parameters. Further studies should focus on optimal surveillance following diagnosis of PE. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Binder J, Palmrich P, Kalafat E, et al. Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia. Ultrasound Obstet Gynecol. 2023. PMID: 37265117. doi:10.1002/uog.26276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。